Edema of the eyelids and sclera after rituximab infusion for orbital MALT lymphoma.
Oribe
Naoya
N
First Department of Internal Medicine (Medicine and Biosystemic Science), Kyushu University Graduate School of Medical Sciences, Fukuoka 812-8582, Japan.
Tanimoto
Tetsuya E
TE
Shimoda
Kazuya
K
Hikiji
Wakako
W
Mitsugi
Kenji
K
Takase
Ken
K
Henzan
Hideho
H
Numata
Akihiko
A
Miyamoto
Toshihiro
T
Fukuda
Takahiro
T
Nagafuji
Koji
K
Harada
Mine
M
D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects*; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D017338:Cladribine / Q000627:therapeutic use; D003131:Combined Modality Therapy; D004487:Edema / Q000209:etiology*; D005134:Eye Neoplasms / Q000188:drug therapy*; D005141:Eyelid Diseases / Q000209:etiology*; D006801:Humans; D007262:Infusions, Intravenous; D018442:Lymphoma, B-Cell, Marginal Zone / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D000069283:Rituximab
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D017338:Cladribine; D000069283:Rituximab